{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:23:03Z","timestamp":1785252183452,"version":"3.55.0"},"reference-count":93,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Acute lymphoblastic leukemia (ALL) and non-Hodgkin\u2019s lymphoma (NHL) are hematological malignancies with high incidence rates that respond relatively well to conventional therapies. However, a major issue is the clinical emergence of patients with relapsed or refractory (r\/r) NHL or ALL. In such circumstances, opportunities for complete remission significantly decline and mortality rates increase. The recent FDA approval of multiple cell-based therapies, Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (Brexucabtagene autoleucel KTE-X19), and Breyanzi (Lisocabtagene Maraleucel), has provided hope for those with r\/r NHL and ALL. These new cell-based immunotherapies use genetically engineered chimeric antigen receptor (CAR) T-cells, whose success can be attributed to CAR\u2019s high specificity in recognizing B-cell-specific CD19 surface markers present on various B-cell malignancies and the subsequent initiation of anti-tumor activity. The efficacy of these treatments has led to promising results in many clinical trials, but relapses and adverse reactions such as cytokine release syndrome (CRS) and neurotoxicity (NT) remain pervasive, leaving areas for improvement in current and subsequent trials. In this review, we highlight the current information on traditional treatments of NHL and ALL, the design and manufacturing of various generations of CAR T-cells, the FDA approval of Kymriah, Yescarta Tecartus, and Breyanzi, and a summary of prominent clinical trials and the notable disadvantages of treatments. We further discuss approaches to potentially enhance CAR T-cell therapy for these malignancies, such as the inclusion of a suicide gene and use of FDA-approved drugs.<\/jats:p>","DOI":"10.3390\/cells13080662","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T03:07:48Z","timestamp":1712718468000},"page":"662","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes"],"prefix":"10.3390","volume":"13","author":[{"given":"Darya","family":"Khvorost","sequence":"first","affiliation":[{"name":"Department of Life Sciences, Los Angeles City College (LACC), 855 N. Vermont Ave., Los Angeles, CA 90029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Kendall","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Los Angeles City College (LACC), 855 N. Vermont Ave., Los Angeles, CA 90029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali R.","family":"Jazirehi","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Los Angeles City College (LACC), 855 N. Vermont Ave., Los Angeles, CA 90029, USA"},{"name":"Department of Biological Sciences, College of Natural and Social Sciences, California State University, Los Angeles (CSULA), Los Angeles, CA 90032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2347810","DOI":"10.1155\/2017\/2347810","article-title":"Multiple Osteolytic Lesions Causing Hypercalcemia: A Rare Presentation of Acute Lymphoblastic Leukemia","volume":"2017","author":"Mahmood","year":"2017","journal-title":"Case Rep. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2014-12-580001","article-title":"Inherited genetic variation in childhood acute lymphoblastic leukemia","volume":"125","author":"Moriyama","year":"2015","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: A comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/jemt.23139","article-title":"Classification of Acute Lymphoblastic Leukemia Using Deep Learning","volume":"81","author":"Rehman","year":"2018","journal-title":"Microsc. Res. Tech."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00521-013-1438-3","article-title":"An Ensemble Classifier System for Early Diagnosis of Acute Lymphoblastic Leukemia in Blood Microscopic Images","volume":"24","author":"Mohapatra","year":"2014","journal-title":"Neural Comput. Appl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-Operative Group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 Revision of the World Health Organization (WHO) Classification of Myeloid Neoplasms and Acute Leukemia: Rationale and Important Changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neubiorev.2015.03.016","article-title":"Neurocognitive Outcomes in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia Treated on Contemporary Treatment Protocols: A Systematic Review","volume":"53","author":"Cheung","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/pbc.25620","article-title":"Treatment of Young Children with CNS-positive Acute Lymphoblastic Leukemia Without Cranial Radiotherapy","volume":"62","author":"Wilejto","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib Crosses the Blood-brain Barrier and is an Efficient Therapy for Central Nervous System Philadelphia Chromosome\u2013positive Leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1002\/cncr.26033","article-title":"Hematopoietic Stem Cell Transplantation Rates and Long-term Survival in Acute Myeloid and Lymphoblastic Leukemia: Real-world Population-based Data from the Swedish Acute Leukemia Registry 1997\u20132006","volume":"117","author":"Juliusson","year":"2011","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4236\/jct.2016.78061","article-title":"Low Dose Total Body Irradiation (600 cGy) as a Conditioning Regimen in Allogenic Hematopoietic Stem Cell Transplant in Children with Acute Lymphoblastic Leukemia","volume":"7","year":"2016","journal-title":"J. Cancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3857\/roj.2014.32.3.198","article-title":"Effects of Total Body Irradiation-Based Conditioning on Allogeneic Stem Cell Transplantation for Pediatric Acute Leukemia: A Single-Institution Study","volume":"32","author":"Park","year":"2014","journal-title":"Radiat. Oncol. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/sj.onc.1207843","article-title":"The epidemiology of non-Hodgkin\u2019s lymphoma","volume":"23","author":"Fisher","year":"2004","journal-title":"Oncogene"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/cncr.22102","article-title":"Adolescents and Young Adults with Cancer: The Scope of the Problem and Criticality of Clinical Trials","volume":"107","author":"Bleyer","year":"2006","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdm563","article-title":"Non-Hodgkin\u2019s Lymphoma in Very Elderly Patients Over 80 Years. A Descriptive Analysis of Clinical Presentation and Outcome","volume":"19","author":"Thieblemont","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1586\/14737140.2015.1023712","article-title":"New Insights into the Epidemiology of Non-Hodgkin Lymphoma and Implications for Therapy","volume":"15","author":"Chihara","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinternmed.2007.125","article-title":"Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century","volume":"168","author":"Pulte","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1517\/17530059.2011.618185","article-title":"Risk Factors of Non-Hodgkin Lymphoma","volume":"5","author":"Zhang","year":"2011","journal-title":"Expert Opin. Med. Diagn."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_24","first-page":"274","article-title":"Surgery for Non-Hodgkin\u2019s Lymphoma","volume":"9","author":"Weledji","year":"2015","journal-title":"Oncol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/annonc\/7.suppl_6.S3","article-title":"New Classification of Low-Grade Lymphoma","volume":"7","author":"Groan","year":"1996","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2012.069757","article-title":"Multicenter Phase II Study Of Plitidepsin In Patients With Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma","volume":"98","author":"Ribrag","year":"2013","journal-title":"Haematologica"},{"key":"ref_27","first-page":"185","article-title":"Signs and Symptoms of Childhood Cancer: A Guide for Early Recognition","volume":"88","author":"Fragkandrea","year":"2013","journal-title":"Am. Fam. Physician"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3322\/canjclin.55.6.368","article-title":"Staging Non-Hodgkin Lymphoma","volume":"55","author":"Armitage","year":"2009","journal-title":"CA Cancer J. Clin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1002\/cncr.31669","article-title":"Toward the Potential Cure of Leukemias in the Next Decade","volume":"125","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1995.13.10.2530","article-title":"Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin\u2019s Lymphoma Using CHOP versus CNOP Chemotherapy","volume":"13","author":"Sonneveld","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin\u2019s Lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/14737140.3.6.767","article-title":"Rituximab (Rituxan\/MabThera): The First Decade (1993\u20132003)","volume":"3","year":"2003","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like Chemotherapy Plus Rituximab versus CHOP-like Chemotherapy Alone in Young Patients with Good-prognosis Diffuse Large-B-cell Lymphoma: A Randomised Controlled Trial by the MabThera International Trial (MInT) group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy Plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone vs Prednisone in Induction Treatment of Pediatric ALL: Results of the Randomized Trial AIEOP-BFM ALL 2000","volume":"127","author":"Zimmermann","year":"2016","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2141.2001.02647.x","article-title":"Outcome of Relapsed or Refractory Childhood B-Cell Acute Lymphoblastic Leukaemia and B-Cell Non-Hodgkin\u2019s Lymphoma Treated with the UKCCSG 9003\/9002 Protocols","volume":"112","author":"Atra","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1089\/hum.2013.075","article-title":"Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia","volume":"24","author":"Barrett","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000496870","article-title":"Chimeric antigen receptor T cells: A race to revolutionize cancer therapy","volume":"46","author":"Subklewe","year":"2019","journal-title":"Transfus. Med. Hemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1021\/bi00458a002","article-title":"A Comparison of Strategies to Stabilize Immunoglobulin Fv-Fragments","volume":"29","author":"Glockshuber","year":"1990","journal-title":"Biochemistry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-Dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2147\/TCRM.S145039","article-title":"Axicabtagene Ciloleucel (KTE-C19), an Anti-CD19 CAR T Therapy for the Treatment of Relapsed\/Refractory Aggressive B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"14","author":"Jain","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T Cells of Defined CD4+:CD8+ Composition in Adult B Cell ALL Patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"OX40 Costimulation by a Chimeric Antigen Receptor Abrogates CD28 and IL-2 Induced IL-10 Secretion by Redirected CD4+ T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin\u2019s Lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of Large, Established Tumor Xenografts with Genetically Retargeted Human T Cells Containing CD28 and CD137 Domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase\/AKT\/bcl-XL Activation and CD8+ T Cell-Mediated Tumor Eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/CJI.0b013e31825898e8","article-title":"Evaluation of \u03b3-Retroviral Vectors that Mediate the Inducible Expression of IL-12 for Clinical Application","volume":"35","author":"Zhang","year":"2012","journal-title":"J. Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zhang, C., Liu, L., Zhong, J.F., and Zhang, X. (2017). Engineering CAR-T cells. Biomark. Res., 5.","DOI":"10.1186\/s40364-017-0102-y"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating Anti-CD19 CAR T-cell Therapy into Clinical Practice for Relapsed\/refractory Diffuse Large B-cell Lymphoma","volume":"132","author":"Chow","year":"2018","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Maloney, D.G. (2019). CAR-T cells. Clin. Lymphoma Myeloma Leuk., S100\u2013S101.","DOI":"10.1016\/j.clml.2019.07.435"},{"key":"ref_53","first-page":"32","article-title":"CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma","volume":"13","author":"Hopfinger","year":"2020","journal-title":"memo-Mag. Eur. Med. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA Approval Summary: Axicabtagene Bouchkouj Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia","volume":"25","author":"Lu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained Remissions with CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children with Relapsed\/Refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/oncolo\/oyac163","article-title":"FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncologist"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients with Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-Year Follow-Up of KTE-X19 in Patients with Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia in ZUMA-3 and Its Contextualization with SCHOLAR-3, an External Historical Control Study","volume":"15","author":"Shah","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma: Primary Analysis of the Phase 3 TRANSFORM Study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KXE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the Eye of the Storm: Immune-mediated Toxicities Associated with CAR-T Cell Therapy","volume":"3","author":"Garcia","year":"2019","journal-title":"Hemasphere"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1053120","DOI":"10.3389\/fimmu.2022.1053120","article-title":"Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance","volume":"13","author":"Qin","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Bagley, S.J., Logun, M., Fraietta, J.A., Wang, X., Desai, A.S., Bagley, L.J., Nabavizadeh, A., Jarocha, D., Martins, R., and Maloney, E. (2024). Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: Phase 1 trial interim results. Nat. Med.","DOI":"10.1038\/s41591-024-02893-z"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Gurney, M., and O\u2019Dwyer, M. (2021). Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13071568"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1002\/ctm2.901","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhang, C., He, M., Xing, W., Hou, R., and Zhang, H. (2024). Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer. BMC Cancer, 24.","DOI":"10.1186\/s12885-023-11806-1"},{"key":"ref_76","first-page":"2132","article-title":"Decoding the multidimensional signatures of resident and expanded natural killer cells generated from perinatal blood","volume":"12","author":"Zhang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_77","first-page":"555682","article-title":"Approaches to Improve Clinical Efficacy of CD19-Redirected Chimeric Antigen Receptor (CD19 CAR) T Cell Immunotherapy of Non-Hodgkin\u2019s Lymphoma","volume":"6","author":"Jazirehi","year":"2017","journal-title":"Cancer Ther. Oncol. Int. J."},{"key":"ref_78","first-page":"403","article-title":"CD19 Chimeric Antigen Receptor (CD19 CAR)-Redirected Adoptive T-Cell Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin\u2019s Lymphomas","volume":"6","author":"Onea","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1208\/s12248-014-9675-7","article-title":"Gene-directed Enzyme Prodrug Therapy","volume":"17","author":"Zhang","year":"2015","journal-title":"AAPS J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1172\/JCI10001","article-title":"Prodrug-activating Systems in Suicide Gene Therapy","volume":"105","author":"Springer","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC Locus with CRISPR\/Cas9 Enhances Tumour Rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/10430340460732463","article-title":"Characterization of CD20-Transduced T lymphocytes as an Alternative Suicide Gene Therapy Approach for the Treatment of Graft-Versus-Host Disease","volume":"15","author":"Serafini","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_83","first-page":"15","article-title":"COX1 and COX2 Tissue Expression: Implications and Predictions","volume":"49","author":"Crofford","year":"1997","journal-title":"J. Rheumatol. Suppl."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.2165\/11208240-000000000-00000","article-title":"Celecoxib: A Review of its Use for Symptomatic Relief in the Treatment of Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis","volume":"71","author":"McCormack","year":"2011","journal-title":"Drugs"},{"key":"ref_85","first-page":"655","article-title":"Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships","volume":"10","author":"Zarghi","year":"2011","journal-title":"Iran J. Pharm. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.clinthera.2009.06.003","article-title":"Celecoxib in the Treatment of Primary Dysmenorrhea: Results From Two Randomized, Double-Blind, Active- and Placebo-Controlled, Crossover Studies","volume":"31","author":"Daniels","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/0019-5154.160511","article-title":"Vorinostat\u2014An Overview","volume":"60","author":"Bubna","year":"2015","journal-title":"Indian J. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-230X(02)86002-X","article-title":"Histone Acetyltransferase and Deacetylases in the Control of Cell Proliferation and Differentiation","volume":"86","author":"Lehrmann","year":"2002","journal-title":"Adv. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1158\/1078-0432.CCR-13-2305","article-title":"COX2-independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis","volume":"20","author":"Gallouet","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1535-7163.425.3.4","article-title":"The Histone Deacetylase Inhibitor Suberic Bishydroxymate Regulates the Expression of Multiple Apoptotic Mediators and Induces Mitochondria\u2014Dependent Apoptosis of Melanoma Cells","volume":"3","author":"Zhang","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1074\/jbc.274.1.264","article-title":"p38 Mitogen-activated Protein Kinase Regulates Cyclooxygenase 2 mRNA Stability and Transcription in Lipopolysacaride-treated Human Monocytes","volume":"274","author":"Dean","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.bcp.2008.08.012","article-title":"Improtance of Bak for Celecoxib-induced Apoptosis","volume":"76","author":"Handrick","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.0307708100","article-title":"Histone Deacetylase Inhibitor Activation of p21WAFI Involves Changes in Promoter-associated Proteins, Including HDAC1","volume":"101","author":"Gui","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/8\/662\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:25:21Z","timestamp":1760106321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/8\/662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":93,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cells13080662"],"URL":"https:\/\/doi.org\/10.3390\/cells13080662","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}